Isotechnika, ILJIN deal

Isotechnika terminated a 2010 deal with ILJIN that granted the pharma's ILJIN Life Science Co. Ltd. subsidiary rights to voclosporin in transplant and autoimmune indications in the U.S. and territories outside of Europe, Canada, Israel, South Africa, China and Taiwan. According to Isotechnika, the move would free it to engage with ILJIN and other companies to secure a more favorable relationship to bring voclosporin to market. ILJIN could not be reached for comment (see BioCentury, Nov. 22, 2010). ...